Certara, Inc. $CERT Shares Purchased by Mendel Money Management

Mendel Money Management raised its holdings in Certara, Inc. (NASDAQ:CERT) by 24.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 134,305 shares of the company’s stock after purchasing an additional 26,740 shares during the period. Mendel Money Management owned about 0.08% of Certara worth $1,571,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Teacher Retirement System of Texas raised its position in shares of Certara by 25.3% in the 2nd quarter. Teacher Retirement System of Texas now owns 5,674,485 shares of the company’s stock valued at $66,391,000 after purchasing an additional 1,145,554 shares in the last quarter. TriaGen Wealth Management LLC acquired a new position in shares of Certara in the 2nd quarter valued at approximately $475,000. Public Employees Retirement System of Ohio raised its position in shares of Certara by 9.2% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 200,068 shares of the company’s stock valued at $2,341,000 after purchasing an additional 16,779 shares in the last quarter. AdvisorNet Financial Inc acquired a new position in shares of Certara in the 2nd quarter valued at approximately $25,000. Finally, Harbor Capital Advisors Inc. raised its position in shares of Certara by 41.3% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 28,670 shares of the company’s stock valued at $335,000 after purchasing an additional 8,376 shares in the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Morgan Stanley assumed coverage on Certara in a research report on Thursday, July 3rd. They issued an “equal weight” rating and a $16.00 target price on the stock. Craig Hallum assumed coverage on Certara in a research report on Monday, September 29th. They issued a “buy” rating and a $16.00 target price on the stock. Barclays upped their target price on Certara from $14.00 to $16.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Certara in a research report on Wednesday, October 8th. Finally, Zacks Research raised Certara from a “strong sell” rating to a “hold” rating in a research report on Friday, September 5th. Six research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Certara presently has an average rating of “Hold” and an average target price of $15.63.

Certara Price Performance

Shares of NASDAQ CERT opened at $12.13 on Wednesday. Certara, Inc. has a twelve month low of $8.64 and a twelve month high of $15.69. The company has a current ratio of 2.16, a quick ratio of 2.16 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of 242.65 and a beta of 1.45. The business has a 50 day simple moving average of $11.73 and a 200-day simple moving average of $11.65.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Certara had a net margin of 1.97% and a return on equity of 5.11%. The firm had revenue of $104.57 million during the quarter, compared to the consensus estimate of $104.14 million. During the same quarter last year, the firm posted $0.07 earnings per share. Certara’s revenue was up 12.1% compared to the same quarter last year. As a group, equities research analysts expect that Certara, Inc. will post 0.28 earnings per share for the current year.

Insider Buying and Selling at Certara

In related news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $10.92, for a total transaction of $559,366.08. Following the completion of the transaction, the insider directly owned 73,979 shares in the company, valued at $807,850.68. This represents a 40.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 2.33% of the company’s stock.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.